ArticleJournal of medical case reports2025
Management of a patient with primary adenocarcinoma of the proximal third of the esophagus: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical esophageal adenocarcinoma is a rare tumor often associated with Barrett's esophagus, and its prevalence is lower than distal esophageal adenocarcinoma. Upper esophageal malignancies are usually squamous cell carcinomata; about 5% of these cases are seen during upper gastrointestinal endoscopy. CASE PRESENTATION: We present a patient (a 39-year-old Iranian man) with invasive adenocarcinoma of the proximal third of the esophagus, who was referred to the hospital with no endoscopic or histopathologic evidence of Barrett's esophagus. We discuss the probable cause of this tumor and treatment options and emphasize the importance of recognizing and managing this rare disease.
conclusionsThis case highlights the rarity of this adenocarcinoma and emphasizes the potential of chemotherapy as a standalone treatment, as well as the need for personalized therapeutic strategies and further research for the management of esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.